Item

Drug Testing: Issues and Challenges in 2025

Authors
Cagney, Tamara
Advisor
Date
2025-05-13
Embargo until
Language
Book title
Publisher
Peer Reviewed
Type
Poster/Presentation
Research Area
Jurisdiction
Other Titles
See at
Abstract

This is a strong presentation about Drug Testing, particularly in the California Region, although other states were included in a general sense.

One of the main topics was Marijuana Regulation: The Drug Enforcement Administration (DEA) is considering rescheduling cannabis from a Schedule I to a Schedule III drug. This shift could have significant implications for the cannabis industry, potentially changing the regulatory landscape, impacting research, and affecting businesses in various ways. Cannabis is currently classified as a Schedule I substance under the Controlled Substances Act (CSA). This means it is considered to have no accepted medical use and a high potential for abuse. Schedule I drugs also face strict regulations that hinder medical research and commercial development. However, the DEA’s consideration of rescheduling reflects growing public opinion on cannabis and mounting scientific evidence supporting its medical benefits.

Data Availibility
Data / Code Location
Table of Contents
Description
Citations
Altmetric:
Series/Report No.
Sponsors
San Francisco EAPA Chapter
Rights/Terms
Attribution-NonCommercial-NoDerivatives 4.0 International
Citation
Identifier to cite or link to this item
Scopus Identifier
Embedded videos